Perl, A., Altman, J., Cortes, J., Levis, M., Smith, C., Litzow, M., … Bahceci, E. (2015). RESULTS OF A FIRST-IN-HUMAN, PHASE 1/2 TRIAL OF ASP2215, A SELECTIVE, POTENT ORAL INHIBITOR OF FLT3/AXL, IN PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA. In HAEMATOLOGICA (Vol. 100, pp. 317–318). Vienna, AUSTRIA: FERRATA STORTI FOUNDATION.

Perl, A., J. Altman, J. Cortes, M. Levis, C. Smith, M. Litzow, M. R. Baer, et al. “RESULTS OF A FIRST-IN-HUMAN, PHASE 1/2 TRIAL OF ASP2215, A SELECTIVE, POTENT ORAL INHIBITOR OF FLT3/AXL, IN PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA.” In HAEMATOLOGICA, 100:317–18. FERRATA STORTI FOUNDATION, 2015.

Perl A, Altman J, Cortes J, Levis M, Smith C, Litzow M, et al. RESULTS OF A FIRST-IN-HUMAN, PHASE 1/2 TRIAL OF ASP2215, A SELECTIVE, POTENT ORAL INHIBITOR OF FLT3/AXL, IN PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA. In: HAEMATOLOGICA. FERRATA STORTI FOUNDATION; 2015. p. 317–8.

Perl, A., et al. “RESULTS OF A FIRST-IN-HUMAN, PHASE 1/2 TRIAL OF ASP2215, A SELECTIVE, POTENT ORAL INHIBITOR OF FLT3/AXL, IN PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA.” HAEMATOLOGICA, vol. 100, FERRATA STORTI FOUNDATION, 2015, pp. 317–18.

Perl A, Altman J, Cortes J, Levis M, Smith C, Litzow M, Baer MR, Claxton D, Erba H, Gill S, Goldberg S, Jurcic J, Larson RA, Liu C, Ritchie E, Sargent B, Schiller G, Spira A, Strickland S, Tibes R, Ustun C, Wang ES, Stuart R, Bahceci E. RESULTS OF A FIRST-IN-HUMAN, PHASE 1/2 TRIAL OF ASP2215, A SELECTIVE, POTENT ORAL INHIBITOR OF FLT3/AXL, IN PATIENTS WITH RELAPSED OR REFRACTORY ACUTE MYELOID LEUKEMIA. HAEMATOLOGICA. FERRATA STORTI FOUNDATION; 2015. p. 317–318.